A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

11.7K views

⸱

DOI:

10.3791/59977

⸱

October 3rd, 2019

 ,  ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

Described are protocols for the highly efficient genome editing of murine hematopoietic stem and progenitor cells (HSPC) by the CRISPR/Cas9 system to rapidly develop mouse model systems with hematopoietic system-specific gene modifications.

Abstract

Manipulating genes in hematopoietic stem cells using conventional transgenesis approaches can be time-consuming, expensive, and challenging. Benefiting from advances in genome editing technology and lentivirus-mediated transgene delivery systems, an efficient and economical method is described here that establishes mice in which genes are manipulated specifically in hematopoietic stem cells. Lentiviruses are used to transduce Cas9-expressing lineage-negative bone marrow cells with a guide RNA (gRNA) targeting specific genes and a red fluorescence reporter gene (RFP), then these cells are transplanted into lethally-irradiated C57BL/6 mice. Mice transplanted with lentivirus expressing non-targeting gRNA are used as controls. Engraftment of transduced hematopoietic stem cells are evaluated by flow cytometric analysis of RFP-positive leukocytes of peripheral blood. Using this method, ~90% transduction of myeloid cells and ~70% of lymphoid cells at 4 weeks after transplantation can be achieved. Genomic DNA is isolated from RFP-positive blood cells, and portions of the targeted site DNA are amplified by PCR to validate the genome editing. This protocol provides a high-throughput evaluation of hematopoiesis-regulatory genes and can be extended to a variety of mouse disease models with hematopoietic cell involvement.

Introduction

Many studies in hematology and immunology rely on the availability of genetically modified mice, including conventional and conditional transgenic/knock-out mice that utilize hematopoietic system-specific Cre drivers such as Mx1-Cre, Vav-Cre, and others1,2,3,4,5. These strategies require the establishment of new mouse strains, which can be time-consuming and financially burdening. While revolutionary advances in genome editing technology have enabled the generation of new mouse strains in as few as 3-4 mont....

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures involving animal subjects have been approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Virginia.

1. Generation and purification of lentivirus particles

NOTE: Lentivirus particles containing the optimized guide RNA can be produced by the detailed protocols provided by Addgene: <https://media.addgene.org/cms/files/Zhang_lab_LentiCRISPR_library_protocol.pdf)>. Optimized methods for high-titer lentivirus preparation and storage are discussed elsewhere17,18. In brief, lentiviruses are produced by co-tr....

Access restricted. Please log in or start a trial to view this content.

Results

Using the above described protocol, approximately 0.8-1.0 x 108 bone marrow cells per mouse have been obtained. The number of lineage-negative cells we obtain is approximately 3 x 106 cells per mouse. Typically, the yield of bone marrow lineage-negative cells is 4%-5% of that of total bone marrow nuclear cells.

Chimerism of transduced cells (RFP-positive) is evaluated by flow cytometry of the peripheral blo.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The advantage of this protocol is the creation of animal models harboring specific mutations in hematopoietic cells in a rapid and highly cost-effective manner compared to conventional mouse transgenic approaches. It was found that this methodology enables the generation of mice with hematopoietic cell gene-manipulations within 1 month. There are several critical steps in this protocol that require further consideration.

Screening of gRNA sequence

.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

S. S. was supported by an American Heart Association postdoctoral fellowship 17POST33670076. K. W. was supported by NIH grants R01 HL138014, R01 HL141256, and R01 HL139819.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
RPMI Medium 1640 (1X)Gibco11875-093Medium
Sulfamethoxazole and Trimethoprim injectionTEVA0703-9526-01
1/2 cc LO-DOSE INSULIN SYRINGEEXELINT26028general supply
293T cellsATCCCRL-3216--Cell line
APC-anti-mouse Ly6C (Clone AL-21)BD Biosciences560599Antibodies
APC-Cy7-anti-mouse CD45R (RA3-6B2)BD Biosciences552094Antibodies
BD Luer-Lok disposable syringes, 10 mlBD309604general supply
BD Microtainer blood collection tubes, K2EDTA addedBD Bioscience365974general supply
BD Precisionglide needle, 18 GBD305195general supply
BD Precisionglide needle, 22 G BD305155general supply
BV510-anti-mouse CD8a (Clone 53-6.7)Biolegend100752Antibodies
BV711-anti-mouse CD3e (Clone 145-2C11)Biolegend100349Antibodies
Collagen from calf skinSigma-Aldrich9007-34-5general supply
Corning Costar Ultra-Low Attachment Multiple Well Plate, 6 well Millipore SigmaCLS3471general supply
CRISPR/Cas9 knock-in miceThe Jackson Laboratory028555mouse
DietGel 76AClear H2O70-01-5022general supply
Dulbecco’s Modified Eagle’s Medium (DMEM) - high glucoseSigma AldrichD6429Medium
eBioscience 1X RBC Lysis BufferThermo fisher Scientific00-4333-57Solution
Falcon 100 mm TC-Treated Cell Culture DishLife Sciences353003general supply
Falcon 5 mL round bottom polystyrene test tubeLife Sciences352054general supply
Falcon 50 mL Conical Centrifuge TubesFisher Scientific352098general supply
Falcon 6 Well Clear Flat Bottom TC-Treated Multiwell Cell Culture Plate Life Science353046general supply
Fisherbrand microhematocrit capillary tubesThermo Fisher Scientific22-362566general supply
Fisherbrand sterile cell strainers, 70 μmFisher Scientific22363548general supply
FITC-anti-mouse CD4 (Clone RM4-5)Invitrogen11-0042-85Antibodies
Fixation BufferBD Bioscience554655Solution
Guide-it Compete sgRNA Screening SystemsClontech632636Kit
Isothesia (Isoflurane) solutionHenry Schein29404Solution
Lenti-X qRT-PCR Titration Kit Takara631235Kit
Lineage Cell Depletion Kit, mouseMiltenyi Biotec130-090-858Kit
Millex-HV Syringe Filter Unit, 0.45 mmMillipore SigmaSLHV004SLgeneral supply
PBS pH7.4 (1X)Gibco10010023Solution
PE-Cy7-anti-mouse CD115 (Clone AFS98)eBioscience25-1152-82Antibodies
PEI MAXPolysciences24765-1Solution
Penicillin-Streptomycin MixtureLonza17-602FSolution
PerCP-Cy5.5-anti-mouse Ly6G (Clone 1A8)BD Biosciences560602Antibodies
pLKO5.sgRNA.EFS.tRFP Addgene57823Plasmid
pMG2DAddgene12259Plasmid
Polybrene Infection/Transfection ReagentSigma AldrichTR-1003-GSolution
Polypropylene Centrifuge TubesBECKMAN COULTER326823general supply
psPAX2 Addgene12260Plasmid
RadDisk – Rodent Irradiator DiskBraintree ScientificIRD-P Mgeneral supply
Recombinant Murine SCFPeprotech250-03Solution
Recombinant Murine TPO Peprotech 315-14Solution
StemSpan SFEMSTEMCELL Technologies09600Solution
TOPO TA cloning kit for sequencing with One Shot TOP10 Chemically Competent E.coliThermo fisher ScientificK457501Kit
Zombie Aqua Fixable Viability KitBioLegend423102Solution 

References

  1. Sasaki, Y., et al. Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells. EMBO Journal. 32, 2463-2476 (2013).
  2. Ogilvy, S., et al. Transcriptional regulation of vav, a gene expressed thro....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Hematopoietic Stem CellsFlow CytometryBone Marrow TransplantationLineage Negative CellsRFP Reporter GeneViral Titer MeasurementPeripheral Blood AnalysisGenomic DNA PCR